US and UK Conclude No-Tariff Pact on Prescription Drugs.

The United Kingdom and the United States have reached a major trade agreement that will keep no duties on UK pharmaceutical products entering the American market.

Key Provisions of the Deal

As part of the deal, the UK has pledged to increase funding on drugs through the National Health Service (NHS). This move secures that tariffs on these crucial products will stay at nothing for a duration of the next three years.

This development follows previous threats to hike tariffs on patented pharmaceutical products, with increases mentioned reaching 100%.

"This arrangement with the Britain reinforces the global environment for innovative medicines and introduces much-needed fairness to transatlantic pharmaceutical trade," a release noted.

Economic Impact

Pharmaceuticals are one of the UK's biggest goods shipped to the US, which is easily the biggest destination for major companies like GSK and AstraZeneca.

Trade data reveal that in the year prior to the third quarter, the UK exported pharmaceutical products valued at billions to the US. This figure made up nearly one-fifth of British export trade in that period.

"This deal protects employment, boosts funding and facilitates the UK to establish itself as a global hub for life sciences," a minister commented.

Detailed UK Commitments

The agreement involves several notable pledges from the British government:

• Revised Affordability Limit: The UK will raise the price threshold at which it considers new treatments to be unaffordable by twenty-five percent.
• Higher Drug Budget: There is a target to double total NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
• Payback Limit: The amount pharmaceutical firms must refund to the NHS to stay within budget will be capped at fifteen percent. Last year, rebates topped twenty percent.

Industry Background

The pact follows a long-running row between the drug companies and the British authorities over drug pricing and NHS adoption.

These tensions were exacerbated by arguments that American consumers were paying a premium for the same drugs than people in the UK and Europe.

In recent months, several large manufacturing plans in the UK have been halted or abandoned, while substantial expansions have been pledged toward US facilities.

A senior figure publicly accepted that the NHS had to increase expenditure on drugs, noting that its spending on drugs had shrunk as a percentage of its overall budget over the past decade.